Axiom Asia has closed its fifth regional fund-of-funds at $1.39 billion - beating the target of $1.01 billion - and also raised $210 million for its first dedicated co-investment vehicle.
The fundraising process began towards the end of 2017 and the final close comes approximately two years after the firm raised just over $1 billion for its fourth fund. Axiom’s deployment strategy is...
Increased climate change awareness on a corporate level is leading to more investment – either direct or through funds – in start-ups that offer mitigation solutions. Asia is a key geography
Healthcare-focused Panacea Venture has led a $40 million Series C round for China’s XWPharma, a neurobiology-focused biotech developer previously known as XW Laboratories.
Kyee Technology, a Chinese digital medical platform has raised RMB430 million ($64 million) in a Series D round led by Tencent Holdings. Other investors include Longmen Capital, Dyee Capital and Royal Sea Capital.
Biocytogen, a Chinese contract research organization (CRO) that provides genetically-modified mice for drug testing, has raised RMB970 million ($143 million) in an extended tranche of Series D funding.